Ionis Pharmaceuticals (IONS) Operating Margin (2009 - 2026)

Ionis Pharmaceuticals' Operating Margin history runs 18 years deep, the most recent figure standing at 47.72% for Q1 2026.

• In Q1 2026, Operating Margin rose 6387.0% year-over-year to 47.72%; the TTM figure through Mar 2026 stood at 57.92% (up 794.0% YoY), while the FY2025 annual figure was 8.45%, up 525.0% from the prior year.
• Operating Margin was 47.72% for Q1 2026 at Ionis Pharmaceuticals, up from 105.47% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 6990.8% in Q2 2025 to a low of 136.95% in Q4 2022.
• Historically, Operating Margin has averaged 340.85% across 5 years, with a median of 63.92% in 2022.
• The sharpest annual moves came in 2022 and 2025: Operating Margin plunged 18709 bps in 2022, then soared 702014 bps in 2025.
• A 5-year view of Operating Margin shows it stood at 136.95% in 2022, then soared by 99 bps to 1.89% in 2023, then sank by 2493 bps to 48.91% in 2024, then slumped by 116 bps to 105.47% in 2025, then jumped by 55 bps to 47.72% in 2026.
• The last three Operating Margin figures came in at 47.72% (Q1 2026), 105.47% (Q4 2025), and 102.21% (Q3 2025), per Business Quant data.